High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types

Annals of Clinical and Translational Neurology

Volumn 1, Issue 10, 2014, Pages 822-832

  Doss, Sarah ^a,p   Wandinger, Klaus Peter ^b   Hyman, Bradley T ^c   Panzer, Jessica A ^d   Synofzik, Matthis ^e,f   Dickerson, Bradford ^c   Mollenhauer, Brit ^g,h   Scherzer, Clemens R ⁱ   Ivinson, Adrian J ⁱ   Finke, Carsten ^a   Schöls, Ludger ^e,f   Müller vom Hagen, Jennifer ^e,f   Trenkwalder, Claudia ^g,h   Jahn, Holger ^j   Höltje, Markus ^a   Biswal, Bharat B ^k   Harms, Lutz ^a   Ruprecht, Klemens ^a   Buchert, Ralph ^a   Höglinger, Günther U ^f,l,m   Oertel, Wolfgang H ^m   Unger, Marcus M ^m,n   Körtvélyessy, Peter ^o   Bittner, Daniel ^f,o   Priller, Josef ^a,f   Spruth, Eike J ^a   Paul, Friedemann ^a,p   Meisel, Andreas ^a   Lynch, David R ^d   Dirnagl, Ulrich ^a,f,q   Endres, Matthias ^a,f,q   Teegen, Bianca ^r   Probst, Christian ^r   Komorowski, Lars ^r   Stöcker, Winfried ^r   Dalmau, Josep ^s   Prüss, Harald ^a,f   more..

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c Massachusetts Alzheimer's Disease Research Center   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^g Paracelsus Elena Klinik   (Germany)

^h UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

ⁱ The Harvard Center for Neurodegeneration & Repair   (United States)

^j UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^k NEW JERSEY INSTITUTE OF TECHNOLOGY   (United States)

^l TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^m PHILIPPS UNIVERSITY MARBURG   (Germany)

ⁿ SAARLAND UNIVERSITY   (Germany)

^o UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^p MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^q Center for Stroke Research   (Germany)

^r Institute of Experimental Immunology   (Germany)

^s UNIVERSITY OF BARCELONA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; DEMENTIA; DISEASE COURSE; EPITOPE MAPPING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIMARY PROGRESSIVE APHASIA; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; RETROSPECTIVE STUDY;

EID: 84938978398     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.120     Document Type: Article

References (35)

1. Flanagan EP, McKeon A, Lennon VA, et al. Autoimmune dementia: clinical course and predictors of immunotherapy response. Mayo Clin Proc 2010;85:881–897.
2. Flanagan EP, Caselli RJ. Autoimmune encephalopathy. Semin Neurol 2011;31:144–157.
3. Lyons MK, Caselli RJ, Parisi JE. Nonvasculitic autoimmune inflammatory meningoencephalitis as a cause of potentially reversible dementia: report of 4 cases. J Neurosurg 2008;108:1024–1027.
4. McKeon A, Marnane M, O'connell M, et al. Potassium channel antibody associated encephalopathy presenting with a frontotemporal dementia like syndrome. Arch Neurol 2007;64:1528–1530.
5. Sabater L, Gaig C, Gelpi E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 2014;13:575–586.
6. Prüss H, Höltje M, Maier N, et al. IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment. Neurology 2012;78:1743–1753.
7. Filippini N, MacIntosh BJ, Hough MG, et al. Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc Natl Acad Sci USA 2009;106:7209–7214.
8. Finke C, Kopp UA, Scheel M, et al. Functional and structural brain changes in anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2013;74:284–296.
9. Beckmann CF, DeLuca M, Devlin JT, Smith SM. Investigations into resting-state connectivity using independent component analysis. Philos Trans R Soc Lond B Biol Sci 2005;360:1001–1013.
10. Apostolova I, Lindenau M, Fiehler J, et al. Detection of a possible epilepsy focus in the residual mesial temporal lobe in a patient operated on a ganglioglioma by ictal and interictal perfusion SPECT only after computer-aided sub-traction analysis: a case report. Nuklearmedizin 2008;47:N65–N68.
11. Wu HY, Hsu FC, Gleichman AJ, et al. Fyn-mediated phosphorylation of NR2B Tyr-1336 controls calpain-mediated NR2B cleavage in neurons and heterologous systems. J Biol Chem 2007;282:20075–20087.
12. Gleichman AJ, Spruce LA, Dalmau J, et al. Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain. J Neurosci 2012;32:11082–11094.
13. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091–1098.
14. Westlye ET, Lundervold A, Rootwelt H, et al. Increased hippocampal default mode synchronization during rest in middle-aged and elderly APOE epsilon4 carriers: relationships with memory performance. J Neurosci 2011;31:7775–7783.
15. Hawellek DJ, Hipp JF, Lewis CM, et al. Increased functional connectivity indicates the severity of cognitive impairment in multiple sclerosis. Proc Natl Acad Sci USA 2011;108:19066–19071.
16. Whitfield-Gabrieli S, Thermenos HW, Milanovic S, et al. Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proc Natl Acad Sci USA 2009;106:1279–1284.
17. Hatzifilippou E, Koutsouraki E, Banaki T, et al. Antibodies against GM1 in demented patients. Am J Alzheimers Dis Other Demen 2008;23:274–279.
18. Karczewski P, Pohlmann A, Wagenhaus B, et al. Antibodies to the alpha1-adrenergic receptor cause vascular impairments in rat brain as demonstrated by magnetic resonance angiography. PLoS One 2012;7:e41602.
19. Bartos A, Fialova L, Svarcova J, Ripova D. Patients with Alzheimer disease have elevated intrathecal synthesis of antibodies against tau protein and heavy neurofilament. J Neuroimmunol 2012;252:100–105.
20. Taguchi H, Planque S, Nishiyama Y, et al. Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease. Autoimmun Rev 2008;7:391–397.
21. Petzold A, Keir G, Lim D, et al. Cerebrospinal fluid (CSF) and serum S100B: release and wash-out pattern. Brain Res Bull 2003;61:281–285.
22. Colasanti T, Barbati C, Rosano G, et al. Autoantibodies in patients with Alzheimer's disease: pathogenetic role and potential use as biomarkers of disease progression. Autoimmun Rev 2010;9:807–811.
23. Prüss H, Finke C, Höltje M, et al. N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol 2012;72:902–911.
24. Hammer C, Stepniak B, Schneider A, et al. Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. Mol Psychiatry 2013; [Epub ahead of print]. doi: 10.1038/mp.2013.110.
25. Titulaer MJ, Kayser MS, Dalmau J. Authors' reply. Lancet Neurol 2013;12:425–426.
26. Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010;133:1655–1667.
27. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12:157–165.
28. Wandinger KP, Saschenbrecker S, Stoecker W, Dalmau J. Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis. J Neuroimmunol 2010;231:86–91.
29. Prüss H, Dalmau J, Harms L, et al. Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. Neurology 2010;75:1735–1739.
30. Steiner J, Teegen B, Schiltz K, et al. Prevalence of N-methyl-D-aspartate receptor autoantibodies in the peripheral blood: healthy control samples revisited. JAMA Psychiatry 2014;71:838–839.
31. Busse S, Brix B, Kunschmann R, et al. N-methyl-D-aspartate glutamate receptor (NMDA-R) antibodies in mild cognitive impairment and dementias. Neurosci Res 2014; pii: S0168-0102(14)00113-8. doi: 10.1016/j.neures.2014.06.002. [Epub ahead of print]
32. Dahm L, Ott C, Steiner J, et al. Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol 2014;76:82–94.
33. Galea I, Bechmann I, Perry VH. What is immune privilege (not)? Trends Immunol 2007;28:12–18.
34. Kowal C, DeGiorgio LA, Nakaoka T, et al. Cognition and immunity; antibody impairs memory. Immunity 2004;21:179–188.
35. Peery HE, Day GS, Dunn S, et al. Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology. Autoimmun Rev 2012;11:863–872.